Advances in the Vaccination of the Elderly Against Influenza: Role of a High-dose Vaccine

Seth J Sullivan; Robert Jacobson; Gregory A Poland


Expert Rev Vaccines. 2010;9(10):1127-1133. 

In This Article

Five-year View

During the next 5 years, HD-TIV will likely become the preferred vaccine for those 65 years and older, if enhanced efficacy over SD-TIV is demonstrated and the current safety profile persists. If so, pending further data that is currently being collected, we expect the vaccine to receive further ACIP scrutiny. It is also likely that the vaccine could be tested and used for younger, immunocompromized individuals such as transplant recipients and HIV-infected patients. We anticipate more data to emerge for these important and vulnerable patient populations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: